NASDAQ · Biotechnology

Denali Therapeutics Inc. (DNLI) Stock

$18.67 -2.56% NASDAQ: DNLI Healthcare

Valuation

MetricValue
Price$18.67
Market Cap$2.96B
P/E Ratio-7.04
P/B Ratio4.49
P/S Ratio880.74
EPS (TTM)$-2.97
52-Week High$27.30
52-Week Low$13.75
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-55.27%
ROA-44.17%
ROCE-50.82%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.03
Current Ratio9.19

Annual Financials (USD)

Metric20212022202320242025
Revenue$49.0M$108.0M$331.0M$0$0
Operating Profit$-296.0M$-341.0M$-197.0M$-487.0M$-555.0M
Net Profit$-291.0M$-326.0M$-145.0M$-423.0M$-513.0M
EPS$-2.39$-2.60$-1.06$-2.57$-2.97
Op Margin-607.8%-314.2%-59.5%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.4B$1.5B$1.2B$1.4B$1.1B
Total Liabilities$442.0M$418.0M$123.0M$144.0M$131.0M
Cash$293.0M$218.0M$127.0M$175.0M$205.0M
Borrowings$64.0M$60.0M$52.0M$49.0M$37.0M

Latest News

Will Recent Setbacks Impact Growth Prospects of DNLI Stock? Zacks · Jul 15, 2026 Acumen Pharmaceuticals Shows Early Alzheimer’s Disease Insights Exec Edge · Jul 15, 2026 Wedbush Raises Price Target on Denali Therapeutics to $26 From $20, Keeps Outperform Rating MT Newswires · Jul 13, 2026 Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s? Barrons.com · Jul 13, 2026 Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier GlobeNewswire · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-211.0M$-245.0M$-358.0M$-348.0M$-413.0M
Investing Cash Flow$-30.0M$-159.0M$236.0M$-105.0M$246.0M
Financing Cash Flow$0$14.0M$0$17.0M$0
Net Cash Flow$-214.0M$-75.0M$-91.0M$48.0M$32.0M
Free Cash Flow$-220.0M$-263.0M$-371.0M$-364.0M$-422.0M

Valuation & Return Ratios

MetricValue
PEG Ratio4.11
EV / EBITDA-6.03
FCF Yield-13.78%
Quick Ratio8.32
Interest Coverage0.00
Return 1Y53.35%
Return 3Y4.62%
Return 5Y-53.51%

Ownership

Insiders Held9.16%
Institutions Held105.04%
Institutions Float Held115.63%
Institutional HolderSharesReport Date
Blackrock Inc.13,034,4342026-03-31
BAILLIE GIFFORD & CO12,066,4792026-03-31
T. Rowe Price Investment Management, Inc.8,519,1922026-03-31
Temasek Holdings (Private) Ltd7,012,9742026-03-31
State Street Corporation6,272,0012026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALECAlector, Inc. $2.02 +5.21% -1.84 $224.27M 0.00%
AMLXAmylyx Pharmaceuticals, Inc. $27.20 -0.84% -19.71 $3.02B 0.00%
BHVNBiohaven Ltd. $11.93 +0.42% -2.77 $1.80B 0.00%
CGTXCognition Therapeutics, Inc. $0.90 -4.42% -4.82 $80.12M 0.00%
IONSIonis Pharmaceuticals, Inc. $43.30 -1.95% -12.57 $7.20B 0.00%

About Denali Therapeutics Inc.

Denali Therapeutics Inc. (DNLI) stock trades at $18.67 with a market capitalization of $2.96B. The stock is valued at a price-to-earnings (P/E) ratio of -7.04, price-to-book of 4.49, price-to-sales of 880.74. Over the past 52 weeks the stock has ranged between $13.75 and $27.30, and currently trades 31.6% below its 52-week high.

On profitability, Denali Therapeutics Inc. generates a return on equity (ROE) of -55.27%, return on capital employed of -50.82%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides